Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China

doi:10.1111/1759-7714.14644

	Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China
	Xu, Chunwei 1,83; Si, Lu 2; Wang, Wenxian 3; Li, Ziming 4; Song, Zhengbo 3; Wang, Qian 5; Liu, Aijun 6; Yu, Jinpu 7; Fang, Wenfeng 8; Zhong, Wenzhao 9
刊名	THORACIC CANCER
	2022-09-20
关键词	fusion precision medicine solid tumor targeted therapy tyrosine receptor kinase
ISSN号	1759-7706
DOI	10.1111/1759-7714.14644
通讯作者	Zhang, Xiaotian(zhangxiaotianmed@163.com) ; Song, Yong(yong.song@nju.edu.cn) ; Lu, Yuanzhi(yuanzhi.lu@jnu.edu.cn)
英文摘要	Gene fusions can drive tumor development for multiple types of cancer. Currently, many drugs targeting gene fusions are being approved for clinical application. At present, tyrosine receptor kinase (TRK) inhibitors targeting neurotrophic tyrosine receptor kinase (NTRK) gene fusions are among the first "tumor agnostic" drugs approved for pan-cancer use. Representative TRK inhibitors, including larotrectinib and entrectinib, have shown high efficacy for many types of cancer. At the same time, several second-generation drugs designed to overcome first-generation drug resistance are undergoing clinical development. Due to the rarity of NTRK gene fusions in common cancer types and technical issues regarding the complexity of fusion patterns, effectively screening patients for TRK inhibitor treatment in routine clinical practice is challenging. Different detection methods including immunohistochemistry, fluorescence in situ hybridization, reverse transcription-polymerase chain reaction, and (DNA and/or RNA-based) next-generation sequencing have pros and cons. As such, recommending suitable tests for individual patients and ensuring the quality of tests is essential. Moreover, at present, there is a lack of systematic review for the clinical efficacy and development status of first- and second-generation TRK inhibitors. To resolve the above issues, our expert group has reached a consensus regarding the diagnosis and treatment of NTRK gene fusion solid tumors, aiming to standardize clinical practice with the goal of benefiting patients with NTRK gene fusions treated with TRK inhibitors.
WOS关键词	INFANTILE FIBROSARCOMA ; MESOBLASTIC NEPHROMA ; MOLECULAR-DETECTION ; ANCHORED MULTIPLEX ; KINASE ; EXPRESSION ; MUTATIONS ; FAMILY ; INHIBITION ; RECEPTORS
WOS研究方向	Oncology ; Respiratory System
语种	英语
出版者	WILEY
WOS记录号	WOS:000855706000001
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/128990]
专题	中国科学院合肥物质科学研究院
通讯作者	Zhang, Xiaotian; Song, Yong; Lu, Yuanzhi
作者单位	1.Nanjing Univ, Affiliated Jinling Hosp, Dept Resp Med, Med Sch, Nanjing 210002, Jiangsu, Peoples R China 2.Peking Univ Canc Hosp & Inst, Dept Melanoma & Sarcoma, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China 3.Chinese Acad Sci Univ Canc Hosp, Dept Chemotherapy, Zhejiang Canc Hosp, Hangzhou, Peoples R China 4.Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Shanghai Lung Canc Ctr, Shanghai, Peoples R China 5.Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Dept Resp Med, Affiliated Hosp, Nanjing, Peoples R China 6.Peoples Liberat Army Gen Hosp, Dept Pathol, Med Ctr 7, Beijing, Peoples R China 7.Tianjin Med Univ Canc Inst & Hosp, Canc Mol Diagnost Core, Tianjin, Peoples R China 8.Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Med Oncol, State Key Lab Oncol South China, Guangzhou, Peoples R China 9.Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Sch Med,Guangdong Prov Lab Translat Med Lung Canc, Guangdong Lung Canc Inst, Guangzhou, Peoples R China 10.Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Dept Med Oncol, State Key Lab Mol Oncol, Beijing, Peoples R China
推荐引用方式 GB/T 7714	Xu, Chunwei,Si, Lu,Wang, Wenxian,et al. Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China[J]. THORACIC CANCER,2022.
APA	Xu, Chunwei.,Si, Lu.,Wang, Wenxian.,Li, Ziming.,Song, Zhengbo.,...&Lu, Yuanzhi.(2022).Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China.THORACIC CANCER.
MLA	Xu, Chunwei,et al."Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China".THORACIC CANCER (2022).